Drug Profile
Budigalimab - AbbVie
Alternative Names: ABBV-181Latest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator AbbVie
- Developer AbbVie; Aceragen
- Class Antineoplastics; Antiretrovirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Non-small cell lung cancer
- Phase II HIV-1 infections; Liver cancer; Pancreatic cancer
- Phase I Small cell lung cancer; Solid tumours; Squamous cell cancer
- No development reported Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 29 Mar 2024 Phase-II/III clinical trials in Non-small cell lung cancer (Metastatic disease, Combination therapy, First-line therapy) in Israel, USA (IV) (NCT06236438) (EudraCT2023-505773-32-00)
- 06 Feb 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in Israel (IV) , (NCT06158958)
- 06 Feb 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) , (NCT06158958)